Drug Trial Radar · NCT03180034
Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study
Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27,945
Actual
Start
Nov 29, 2017
Primary completion
Aug 21, 2025
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- Bill and Melinda Gates Foundation
- First posted
- Jun 8, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 12 years, up to 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This phase IV trial investigates whether one dose of a human papillomavirus vaccine works as well as two doses in preventing human papillomavirus (HPV) infection. Certain types of HPV cause almost all cases of cervical cancer. Vaccines that protect against infection with these types of human papillomavirus may reduce the risk of cervical cancer. Both Gardasil-9 and Cervarix protect against HPV 16 and 18, which cause 70% of all cervical cancers. However, HPV vaccination rates are too low, especially in countries with very high rates of cervical cancer. HPV vaccines are expensive-many countries cannot afford them-more than one dose is needed, and giving multiple doses is difficult. Researchers want to find out if one dose prevents HPV infection. If it does, more people might get the vaccine.
Conditions
- Human Papillomavirus Infection
- Human Papillomavirus-Related Cervical Carcinoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine AdsorbedBiological
Given IM
Questionnaire AdministrationOther
Ancillary studies
Recombinant Human Papillomavirus Bivalent VaccineBiological
Given IM
Recombinant Human Papillomavirus Nonavalent VaccineBiological
Given IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of at least one incident persistent human papillomavirus (HPV)-16 and/or HPV-18 cervical infections, counted cumulatively over the follow-up visitsTime frame: Months 12 to 60
- Incident persistent HPV-16 and/or HPV-18 cervical infectionsTime frame: Months 54 and 60
- Persistent HPV-16 and/or HPV-18 cervical infections (End-of-Study Survey Cohort)Time frame: Baseline, and 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Agencia Costarricense de Investigaciones Biomédicas (ACIB)
Liberia, Guanacaste Province, Costa Rica
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.